Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Tokyo-based Arigen Out-licenses Ulcer Drug To Korean CJ CheilJedang

This article was originally published in PharmAsia News

Executive Summary

Tokyo-based biotech venture firm aRigen Pharmaceutical out-licensed the rights to ulcer drug ARH-1029 in Korea to Seoul-based Korean food and drug conglomerate CJ CheilJedang

Tokyo-based biotech venture firm aRigen Pharmaceutical out-licensed the rights to ulcer drug ARH-1029 in Korea to Seoul-based Korean food and drug conglomerate CJ CheilJedang.

The financial terms were not disclosed. CJ aims to develop the drug and commercialize it in five years. ARH-1029 targets bactericidal activities of Helicobacter pylori, the cause of peptic ulcer and gastritis. The drug is ARigen's first blockbuster candidate and the company has licensed the rights in Japan to Taiho Pharmaceutical in 2009. (Click here for more - Japanese language)

"Arigen Licenses Anti-ulcer Drug Rights TO Korean Pharmaceutical Firm" - Nikkei Sangyo News (5/13/2010)

Table

View full table

Tags:
Latest Headlines

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

Biogen Sees Improving Momentum In Slow Leqembi Launch

Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative

Day One Springs Into Commercial Action With Ojemda Approval

See All
UsernamePublicRestriction

Register

SC074844

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By